Trial Profile
The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf) in Advanced Patients Harboring the V600 BRAF Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2015
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Colorectal cancer; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 13 May 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 12 May 2015 New trial record